FDA approval and dividend move put Pfizer in focus

Pfizer (PFE) has drawn fresh attention after the FDA approved a new maintenance use for IBRANCE in HR+, HER2+ metastatic breast cancer, along with a board decision to declare a third quarter 2026 dividend.

Despite fresh interest around the IBRANCE approval and the upcoming dividend, Pfizer’s share price has been weak over 2026, with a 30 day share price return down 6.13% and a 90 day share price return down 11.65%. The 1 year total shareholder return is slightly positive at 0.67%, pointing to fading momentum but some offset from dividends.

If this kind of mixed sentiment around Pfizer has you thinking about where else growth and income might intersect in healthcare, it could be worth checking out 40 healthcare AI stocks.

Bulls point to Pfizer’s high yield, low P/E and fresh IBRANCE approval, while bears focus on revenue declines, patent risk and a recent downgrade. Which side do the current valuation and cash flow numbers lean toward next?

Most Popular Narrative: 18% Undervalued

With Pfizer last closing at $24.05 against a narrative fair value of about $29.19, the current setup frames a gap that hinges on how investors view the pipeline and long term earnings power.

Robust expansion of Pfizer's late stage pipeline, especially in oncology and rare diseases, with multiple high potential launches and label expansions (e.g., Elrexfio in multiple myeloma, SV in non small cell lung cancer, advanced ADC portfolio, and pipeline vaccines), stands to drive sustained long term revenue and earnings growth by addressing rising global demand for innovative therapies as the population ages.

The fair value depends on how much earnings can grow even as revenue expectations point lower, and on a future earnings multiple above today’s level. Curious what has to happen for that to hold?

Result: Fair Value of $29.19 (UNDERVALUED)

However, the Pfizer narrative still hinges on policy and patent risks, with drug pricing reforms and the approaching patent cliff both capable of challenging today’s upside case.

Next Steps

If the mixed tone around Pfizer leaves you unsure, now is a good time to review both sides of the story and weigh the 2 key rewards and 4 important warning signs.

Looking for more investment ideas beyond Pfizer?

If Pfizer has you reassessing your portfolio mix, now is the moment to broaden your watchlist and put fresh, well filtered opportunities on your radar.

• Target potential value opportunities by scanning 45 high quality undervalued stocks to find candidates that pair solid fundamentals with prices that look appealing on the numbers.
• Strengthen your income stream by reviewing 9 dividend fortresses to identify candidates that combine higher yields with a focus on resilience.
• Dial back volatility risk by focusing on 74 resilient stocks with low risk scores to highlight candidates that score well on financial stability and consistency.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.